The global dialysis equipment market is on a strong growth trajectory, with projected sales expected to increase from USD 11,126.0 million in 2024 to an impressive USD 17,780.9 million by 2034. This ...

The global continuous renal replacement therapy market is set for significant expansion, with projections indicating a surge ...

Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted Talphera's focus on ...

We are delighted that QUELIMMUNE is now available to treat severely ill children at yet another prominent academic medical center,” said Tim Varacek, SeaStar Medical Senior Vice President, Commercial ...

The trial is assessing the efficacy and safety of the company's selective cytopheretic device (SCD) in conjunction with continuous renal replacement therapy (CRRT). The trial aims to enrol 200 adult ...

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces ...

The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with SCD in addition to CRRT as the standard of care, compared with the control group ...

Nutritional interventions, including nutritional counseling, oral supplements, and intradialytic parenteral nutrition (IDPN), are recommended to address these challenges. On dialysis days ...

the agency agreed to two other changes to broaden the clinical study inclusion criteria which would allow the Company to enroll patients already on continuous renal replacement therapy (CRRT ...

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today ...